Compare AGEN & AIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGEN | AIRS |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.8M | 328.7M |
| IPO Year | 1999 | 2021 |
| Metric | AGEN | AIRS |
|---|---|---|
| Price | $7.70 | $2.64 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 946.0K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | $42,877,086.00 | ★ $151,818,000.00 |
| Revenue This Year | $107.63 | $5.19 |
| Revenue Next Year | N/A | $5.32 |
| P/E Ratio | $8.14 | ★ N/A |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $2.71 | $1.51 |
| 52 Week High | $8.85 | $12.00 |
| Indicator | AGEN | AIRS |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 32.49 |
| Support Level | $2.97 | $2.43 |
| Resistance Level | $8.76 | $3.36 |
| Average True Range (ATR) | 0.58 | 0.26 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 60.69 | 5.13 |
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.